Gapping up
In reaction to strong earnings/guidance: LITB +10.1%, NKE +7.9%, PRGS +7.8%, MU +6.3%, DMND +5.2%, THO +4%
Select EU financial related names showing strength: UBS +1.1%, HSBC +1.1%, SAN +0.6%
Other news: NAVB +12.9% (Lymphoseek recommended by CHMP for European approval in sentinel lymph node detection for melanoma, breast and certain head and neck cancers), RPRX +11.6% (Androxal second pivotal study achieves superiority in top line analysis for both co-primary endpoints versus marketed topical gel in the treatment of secondary hypogonadism; also reports it has been granted a Type B Pre-NDA meeting with the FDA in the first half of November), WTSL +11.1% appointed Jon Kubo to newly created position of Executive Vice President and Chief Digital Officer), GALE +9.9% (announced the release of a report prepared by the former Special Committee of Galena's Board of Directors; committee found no evidence that the company was aware that DTG paid bloggers to write favorable articles), AIXG +5.7% (still checking), VNET +5.4% (and Microsoft (MSFT) announce WebDirect Payment Services for Windows Azure services in China), CNET +4.8% (cont momentum higher), SNHY +2.8% (announced special dividend of $1 per share), HIMX +2.6% (still checking, may be related to MU sympathy), GTI +2.2% (modestly retracing losses from earlier this week), CYBR +1.9% (cont momentum following IPO), UA +1.8% (following NKE results), IG +1.7% (cont strength following yest's advance, also pos note from OPCO), SNDK +1.5% (following MU results), GILD +1.5% (European CHMP adopts positive opinion for Gilead's Harvoni (ledipasvir/sofosbuvir) for the treatment of chronic hepatitis C infection in adults), AAPL +1% (issues iOS 8.02 to fix issues with iOS 8.01, according to reports)
Analyst comments: AIXG +5.7% (upgraded to Overweight from Equal-Weight at Morgan Stanley), CLDX +2.8% (initiated with a Outperform at Cowen), VRNT +2.7% (initiated with a Buy at Goldman), CMC +2% (upgraded to Buy from Neutral at Citigroup), LNKD +1.7% (upgraded to Outperform from Market Perform at Cowen), PHG +1.6% (upgraded to Overweight from Equal-Weight at Morgan Stanley), BBBY +1.2% (target raised to $87 from $78 at Williams Capital Group), IVR +1.1% (upgraded to Buy from Neutral at BofA/Merrill), HTS +0.9% (upgraded to Neutral from Underperform at BofA/Merrill), NOC +0.8% (upgraded to Buy from Hold at Deutsche Bank), MO +0.7% (upgraded to Buy from Neutral at BofA/Merrill), WBC +0.5% (upgraded to Buy from Hold at Stifel)
In reaction to strong earnings/guidance: LITB +10.1%, NKE +7.9%, PRGS +7.8%, MU +6.3%, DMND +5.2%, THO +4%
Select EU financial related names showing strength: UBS +1.1%, HSBC +1.1%, SAN +0.6%
Other news: NAVB +12.9% (Lymphoseek recommended by CHMP for European approval in sentinel lymph node detection for melanoma, breast and certain head and neck cancers), RPRX +11.6% (Androxal second pivotal study achieves superiority in top line analysis for both co-primary endpoints versus marketed topical gel in the treatment of secondary hypogonadism; also reports it has been granted a Type B Pre-NDA meeting with the FDA in the first half of November), WTSL +11.1% appointed Jon Kubo to newly created position of Executive Vice President and Chief Digital Officer), GALE +9.9% (announced the release of a report prepared by the former Special Committee of Galena's Board of Directors; committee found no evidence that the company was aware that DTG paid bloggers to write favorable articles), AIXG +5.7% (still checking), VNET +5.4% (and Microsoft (MSFT) announce WebDirect Payment Services for Windows Azure services in China), CNET +4.8% (cont momentum higher), SNHY +2.8% (announced special dividend of $1 per share), HIMX +2.6% (still checking, may be related to MU sympathy), GTI +2.2% (modestly retracing losses from earlier this week), CYBR +1.9% (cont momentum following IPO), UA +1.8% (following NKE results), IG +1.7% (cont strength following yest's advance, also pos note from OPCO), SNDK +1.5% (following MU results), GILD +1.5% (European CHMP adopts positive opinion for Gilead's Harvoni (ledipasvir/sofosbuvir) for the treatment of chronic hepatitis C infection in adults), AAPL +1% (issues iOS 8.02 to fix issues with iOS 8.01, according to reports)
Analyst comments: AIXG +5.7% (upgraded to Overweight from Equal-Weight at Morgan Stanley), CLDX +2.8% (initiated with a Outperform at Cowen), VRNT +2.7% (initiated with a Buy at Goldman), CMC +2% (upgraded to Buy from Neutral at Citigroup), LNKD +1.7% (upgraded to Outperform from Market Perform at Cowen), PHG +1.6% (upgraded to Overweight from Equal-Weight at Morgan Stanley), BBBY +1.2% (target raised to $87 from $78 at Williams Capital Group), IVR +1.1% (upgraded to Buy from Neutral at BofA/Merrill), HTS +0.9% (upgraded to Neutral from Underperform at BofA/Merrill), NOC +0.8% (upgraded to Buy from Hold at Deutsche Bank), MO +0.7% (upgraded to Buy from Neutral at BofA/Merrill), WBC +0.5% (upgraded to Buy from Hold at Stifel)